Profile of vemurafenib-induced severe skin toxicities - Archive ouverte HAL Access content directly
Journal Articles Journal of the European Academy of Dermatology and Venereology Year : 2016

Profile of vemurafenib-induced severe skin toxicities

(1, 2, 3) , (1, 3, 2) , (1, 3, 2) , (1, 3, 2) , (1, 3, 4) , (1, 3, 2) , (1, 3, 2) , (1, 3, 2) , (1, 3, 2)
1
2
3
4

Abstract

BACKGROUND: Vemurafenib, a BRAF inhibitor, is commonly associated with skin toxicity. The impact of severe forms is unknown. OBJECTIVE: To determine the rate of permanent vemurafenib discontinuation due to grade 3-4 skin toxicity, features of these toxicities, their recurrence rate after a switch to dabrafenib and their impact on overall survival. METHODS: Retrospective cohort study of 131 patients treated with vemurafenib for melanoma between November 2010 and December 2014. Data on skin toxicities, the need for vemurafenib adjustment and the impact of switching to dabrafenib were collected. Regarding survival analysis, a conditional landmark analysis was performed to correct lead-time bias. RESULTS: Among the 131 vemurafenib-treated patients, 26% developed grade 3-4 skin toxicity. Forty-four percent of them permanently discontinued their treatment, mainly due to rash and classic skin adverse reactions (Steven-Johnson syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms). Conversely, photosensitivity and carcinomas rarely required treatment adjustment. Grade 3-4 rashes were associated with clinical or biological abnormalities in 94% of patients. Among the 10 patients who subsequently switched to dabrafenib, skin toxicity recurred only in one patient. Overall survival was significantly prolonged in case of severe skin toxicity emerging within the first 4 (P = 0.014) and 8 weeks (P = 0.038) on vemurafenib, with only a trend at 12 weeks (P = 0.052). Median overall survival was also prolonged in case of severe rash. CONCLUSION: In this study, vemurafenib was continued in 56% of patients with grade 3-4 skin toxicity, which was associated with prolonged overall survival when emerging within the first 4 and 8 weeks of treatment. While developing severe skin adverse reactions permanently contraindicates vemurafenib use, other rashes should lead to retreatment attempts with dose reduction. In case of recurrence, dabrafenib seems to be an interesting option. For other skin toxicities, including photosensitivity and cutaneous carcinoma, treatment adjustment is usually not needed.
Embargoed file
Embargoed file
Ne sera jamais visible
Loading...

Dates and versions

inserm-01819814 , version 1 (21-06-2018)

Identifiers

Cite

Lucie Peuvrel, Gaelle Quéreux, Mélanie Saint-Jean, A. Brocard, Jean Michel Nguyen, et al.. Profile of vemurafenib-induced severe skin toxicities. Journal of the European Academy of Dermatology and Venereology, 2016, 30 (2), pp.250 - 257. ⟨10.1111/jdv.13443⟩. ⟨inserm-01819814⟩
44 View
1 Download

Altmetric

Share

Gmail Facebook Twitter LinkedIn More